Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pancreatic Cancer Therapy Area Pipeline Report

http://www.reportlinker.com/p0472369/Pancreatic-Cancer-Therapy-Area-Pipeline-Report.html

The Pancreatic Cancer Therapy Area Pipeline Report contains detailed information on the pancreatic cancer drug pipeline. This report provides insight into the pipeline status of pancreatic cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

• Keep track of your competitors and partners by better understanding their product pipeline.

• Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

• Maintain a critical competitive advantage.

Epidemiology Report

% of Products by Phase of Development

No. of Products by Phase of Development

Marketed Products vs. Pipeline Products

Company Overview - Pipeline Projects

Legend

--Top 5 Companies in Early Stage Pancreatic Cancer Products

--Top 5 Companies in Late Stage Pancreatic Cancer Products

--Top 5 Companies in Marketed Pancreatic Cancer Products

Patent Expirations

Upcoming Milestones

Product Sales

Full Pipeline View

--Product Details : Unknown/Research

--Product Details : Pre Clinical

--Product Details : Phase I

--Product Details : Phase II

--Product Details : Phase III

--Product Details : Pending Approval

--Product Details : On the Market

News Updates

--Product Updates

--Regulatory

To order this report:

Therapy Industry: Pancreatic Cancer Therapy Area Pipeline Report

Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.